Indonesian Political, Business & Finance News

Bio Farma Opens Door to Partnership on Formulating M72 TB Vaccine Candidate

| Source: Antara (Indonesian) Translated from Indonesian | Business
Bio Farma Opens Door to Partnership on Formulating M72 TB Vaccine Candidate
Image: Antara (Indonesian)

Badung, Bali (ANTARA) — State-owned pharmaceutical company PT Bio Farma is open to partnerships to formulate the M72/AS01E tuberculosis (TB) vaccine candidate in Indonesia.

Bio Farma Commercial Director Fitri Puspadewi said this on Thursday during the 40th Stop TB Partnership Board Meeting in Badung Regency, Bali.

“We want Indonesia to be better prepared to meet demand for next-generation TB vaccines. For the M72 candidate, we see an opportunity to work with partners on domestic formulation,” Fitri said.

Pharmaceutical company GSK has developed M72/AS01E through Phase 2 clinical trials.

In July 2026, Gates MRI announced an agreement with the Serum Institute of India to prepare for production of the M72 antigen. The announcement also referred to plans to involve local manufacturers in Indonesia and South Africa in parts of the supply chain.

Fitri said formulation in Indonesia would require an agreement with a partner, while commercial production would depend on clinical trial results and regulatory approval.

The World Health Organization ranked Indonesia second after India by estimated number of people with TB in 2024.

In diagnostics, Bio Farma has partnered with Becton Dickinson (BD) to supply and distribute TB testing devices.

Fitri also highlighted the potential of Near Point of Care (NPOC) molecular tests, such as Pluslife’s MiniDock MTB, for use in primary-care facilities.

“We want people to have easier access to initial TB screening. If molecular testing devices are available at community health centres, patients can be tested closer to where they live,” Fitri said.

The WHO recommends tests in this class for the initial diagnosis of adolescents and adults with symptoms or a positive screening result for pulmonary TB.

More from 5 November 2026 →

Cite this article
Source: jawawa.id (https://jawawa.id/newsitem/bio-farma-opens-door-to-partnership-on-formulating-m72-tb-vaccine-candidate-1793879673)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5834479/bio-farma-buka-peluang-kerja-sama-formulasi-kandidat-vaksin-tb-m72), translated from Indonesian
Print